Literature DB >> 32205722

Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.

Dario Cattaneo1,2, Agostino Riva3, Paola Columpsi4, Giuseppe Lapadula4, Carlo Filice5, Cristina Gervasoni1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32205722     DOI： 10.1097/QAI.0000000000002352

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  1 in total

1.  Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.

Authors:  Matthew L Romo; Ellen Brazier; Dominique Mahambou-Nsondé; Reneé De Waal; Christine Sekaggya-Wiltshire; Cleophas Chimbetete; Winnie R Muyindike; Gad Murenzi; Cordelia Kunzekwenyika; Thierry Tiendrebeogo; Josephine A Muhairwe; Patricia Lelo; Anastase Dzudie; Christelle Twizere; Idiovino Rafael; Oliver C Ezechi; Lameck Diero; Marcel Yotebieng; Lukas Fenner; Kara K Wools-Kaloustian; N Sarita Shah; Denis Nash
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.